BIODEGRADABLE IMPLANT FOR ESTROGEN REPLACEMENT THERAPY

Information

  • Research Project
  • 2651468
  • ApplicationId
    2651468
  • Core Project Number
    R41HD036579
  • Full Project Number
    1R41HD036579-01
  • Serial Number
    36579
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/1/1998 - 27 years ago
  • Project End Date
    3/31/1999 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    4/1/1998 - 27 years ago
  • Budget End Date
    3/31/1999 - 26 years ago
  • Fiscal Year
    1998
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/7/1998 - 27 years ago
Organizations

BIODEGRADABLE IMPLANT FOR ESTROGEN REPLACEMENT THERAPY

ESCRIPTION: (adapted from the applicant's abstract) Donald Monkhouse of herics, Inc. submits this Phase I application to develop an implantable ong term, biodegradable delivery system for ethinyl estradiol. Past ttempts to produce such systems have been unsuccessful because they rovided only short periods of variable drug delivery and non-reproducible iodegradation characteristics. The applicant states that there is, herefore, a currently unmet need for long term delivery systems that can e used in postmenopausal estrogen replacement therapy. This need might e met, he believes by implanting biodegradable polymers that delivery rug with zero-order kinetics. Such a system could be fabricated using heriFormTM technology to construct the polymer implants. During Phase I he applicant intends to design and fabricate four different implants, ach of which has unique internal architecture, spatial distribution of rug and excipient chemistry. His specific aims, during this effort, nclude 1) selecting appropriate excipient materials for four individual tructural implant designs, 2) evaluation of these prototypes for rate and xtent of estrogen release plus polymer degradation in vitro, and 3) evelopment of alternative design options for the best candidate rototypes through mathematical analysis of the initial data using heriSysTM expert, a design program. This plan it expected to provide a elivery system that can then be tested in vivo during a Phase II study. PROPOSED COMMERCIAL APPLICATION: Potential commercial application not available.

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
  • Activity
    R41
  • Administering IC
    HD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    865
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    THERICS, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    MORRISVILLE
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    19067
  • Organization District
    UNITED STATES